CymaBay's seladelpar has the potential to raise the bar in treatment for PBC
Outsourcing Pharma
FEBRUARY 25, 2024
Results from a phase 3 trial looking at treatment for primary biliary cholangitis (PBC) are 'genuinely exciting' and supports the potential for seladelpar to raise the bar in treatment of the disease.
Let's personalize your content